Business Context and Reporting Period
This Form 8-K Current Report, dated March 17, 2026, details the completion of the first step in a two-step redomestication process by Oncolytics Biotech Inc. The Company, previously incorporated in Alberta, Canada, has successfully changed its jurisdiction of incorporation to British Columbia, Canada (the "Continuance"). The Company is an emerging growth company and its common shares trade on The Nasdaq Stock Market LLC under the ticker symbol "ONCY."
Key Financial Metrics
This filing is a corporate governance report regarding a change in jurisdiction and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes Versus Prior Period
- Jurisdiction Change: The Company's legal domicile shifted from Alberta, Canada, to British Columbia, Canada, effective March 17, 2026.
- Governing Law: The Company is now governed by the Business Corporations Act (British Columbia) (BCBCA) rather than the Business Corporations Act (Alberta) (ABCA).
- Shareholder Rights: Material modifications to the rights of security holders occurred due to the adoption of new Articles of Incorporation under British Columbia law. Specific differences are detailed in the referenced Circular/Prospectus.
- Share Structure: Outstanding common shares of Oncolytics Alberta automatically became common shares of Oncolytics British Columbia without change to the number of shares or ticker symbol. The CUSIP (682310875) and ISIN (CA6823108759) remained unchanged at this stage.
Guidance, Outlook, and Risks
Future Domestication: The Company expects to complete the second step of its redomestication on March 31, 2026, by moving its jurisdiction from British Columbia to the State of Nevada, USA (the "Domestication"). Upon this completion, shares will become common stock of Oncolytics Nevada with a par value of $0.001 per share.
Identifier Changes: Effective April 1, 2026, the CUSIP number will change to 68237V103 and the ISIN to US68237V1035.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Risks include the possibility that the anticipated timing and completion of the Domestication may differ from expectations. The Company references risk factors in its Circular/Prospectus and its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Investor Verification Checklist
- Verify the effective date of the second step of redomestication (Nevada) scheduled for March 31, 2026.
- Confirm the new CUSIP (68237V103) and ISIN (US68237V1035) effective April 1, 2026, for trading and settlement purposes.
- Review the "Annex J" section of the Circular/Prospectus to understand specific material differences between Alberta and British Columbia corporate laws affecting shareholder rights.
- Monitor subsequent filings for the Certificate of Domestication confirming the move to Nevada.